Impact BioMedical Inc.

0.40
-0.04 (-8.47%)
At close: Apr 17, 2025, 3:59 PM
0.41
1.13%
After-hours: Apr 17, 2025, 08:00 PM EDT

Company Description

Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare.

It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone.

The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.

In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications.

The company was incorporated in 2018 and is based in Houston, Texas.

Impact BioMedical Inc.
Impact BioMedical Inc. logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Frank D. Heuszel Esq., J.D.

Contact Details

Address:
1400 Broadfield Blvd.
Houston, Texas
United States
Website https://www.impactbiomedinc.com

Stock Details

Ticker Symbol IBO
Exchange AMEX
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001834105
CUSIP Number 45259L205
ISIN Number US45259L2051
Employer ID 85-3926944
SIC Code 2834

Key Executives

Name Position
Frank D. Heuszel Esq., J.D. Chairman & Chief Executive Officer
Mark J. Suseck Chief Operating Officer
Todd D. Macko CPA Chief Financial Officer. Secretary & Treasurer

Latest SEC Filings

Date Type Title
Apr 07, 2025 4 Filing
Apr 07, 2025 4 Filing
Apr 04, 2025 4 Filing
Apr 04, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 03, 2025 8-K Current Report
Apr 02, 2025 SCHEDULE 13D Filing
Apr 02, 2025 4 Filing
Mar 28, 2025 4 Filing
Mar 28, 2025 10-K Annual Report
Mar 28, 2025 8-K Current Report